The biotech sector has started 2015 with the announcement of several deals. Both Kite Pharma (KITE – Snapshot Report) and Isis Pharmaceuticals (ISIS – Analyst Report) saw their share prices increasing on collaboration agreements with major companies. Meanwhile, Alkermes (ALKS – Analyst Report) has also started the year on a positive note with encouraging pipeline data.Recap of the Week’s Most […]
SummaryBiotech stocks should outperform the market in 2015. However the biotech sector is linked to healthcare fundamentals like government pricing policy.
The industry is better financed than any time in its history driving innovation and new product growth. The appetite for M&A and IPOs will continue.
Biopharmaceutical stocks defy traditional analysis and have been a safe haven from global economic news.
2015: Another […]
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.
How Consolidated Water Stands Out In A Strong Industry
Investors Failed To Catch Breitburn Energy Partners, Did You?
See original:
Biotech Stocks Make Big Moves In Final Days Of 2014 … – Benzinga
[…]
The bull market is nearing six years old. It turns out that the biotech sector again managed a huge outperforming year in 2014 as well. The gains of the key biotech exchange traded funds (ETFs) were up in the 40% range, with the NYSE Arca Biotech index up over 45% year-to-date. The equal-weight biotech ETF performed better than the key larger […]
The bull market is nearing six years old. It turns out that the biotech sector again managed a huge outperforming year in 2014 as well. The gains of the key biotech exchange traded funds (ETFs) were up in the 40% range, with the NYSE Arca Biotech index up over 45% year-to-date. The equal-weight biotech ETF performed better than the key larger […]
“Out with the old and in with the new” also applies to the stock market, although the market doesn’t always precisely follow the calendar.Healthcare stocks, which have been superior performers since 2011, lost their mojo this year, and last week they officially suffered a breakdown relative to the market. But as one season turns into the next, new sectors are […]
SummaryThere has definitely been a sector rotation out of biotech stocks and into the consumer goods names that pay high dividend yields.
Amgen remains fairly valued based on 2015 earnings estimates.
The dividend is small but investors received a 29.5% increase to the dividend in the next quarter.
The last time I analyzed Amgen Inc. (NASDAQ:AMGN) on November 25, 2014, I stated, “More […]
Read this article:
Biotech Stocks Sell Off, ETFs Fall Over 5% – iShares NASDAQ …
[…]
Biotech stocks to buy in 2015: Biotech was one of the most profitable sectors this year. Through Dec. 18, the S&P 500 Biotechnology Index is up 43.6% in 2014, and the Nasdaq Biotechnology Index is up 36.9%.Those gains are three to six times as big as the broader markets’. In 2014 through Dec. 18, the Dow Jones Industrial Average is […]
By Ben LevisohnRBC’s Michael Yee and team explain why Celgene (CELG), Biogen Idec (BIIB), Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN) and Regeneron Pharmaceuticals (REGN) are their top biotech stocks for 2015:
Bloomberg News
Top-five longs: Celgene, Biogen Idec, BioMarin Pharmaceutical, Vertex Pharmaceuticals, Regeneron Pharmaceuticals: 1) Celgene we predict “settlement” with Actavis (ACT) could happen after spring when expert discovery ends and before Court begins mid-15; plus investors should start giving […]
